CVS to Cover Lilly GLP-1 Medications for Weight Management
CVS will add coverage for two GLP-1 medications produced by Eli Lilly. The decision expands access for millions of Americans seeking treatment for weight management.
MarketWatchThe medications are the oral tablet Foundayo and the injectable Zepbound.
MarketWatch reported that the coverage change will take effect soon. The move follows earlier decisions by other insurers to add similar products to their formularies.
MarketWatch stated that millions of additional Americans may now qualify for coverage. Patients will still need a prescription and meet plan-specific clinical criteria. No timeline was provided for when the new coverage will appear in member portals or pharmacy systems.
Key Facts
Potential Impact
- 01
More plan members may receive coverage for the listed medications.
- 02
Pharmacies may see higher prescription volume for the two products.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.